News & Press

Mercator Bullfrog Device Being Used in New Proteon Therapeutics Study

Proteon Therapeutics Announces First Patient Dosed in Phase 1 Study Evaluating Vonapanitase for the Treatment of Peripheral Artery Disease Below the Knee

WALTHAM, Mass. – November 10, 2016 – Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced the first patient was dosed in a Phase 1 clinical study evaluating a single administration of investigational drug vonapanitase delivered immediately following angioplasty to patients with peripheral artery disease (PAD).

Continue Reading

Providence Medical Technology Announces the Launch of CAVUX™ Cervical Cage-L and DTRAX® Spinal System-L

WALNUT CREEK, Calif.Nov. 7, 2016 /PRNewswire/ — Providence Medical Technology, Inc., an innovator in tissue-sparing cervical fusion technology, today announced the commercial launch of its new CAVUX Cervical Cage-L and DTRAX Spinal System-L.

Continue Reading

Late-Breaking Clinical Trial Data Presented from Mercator MedSystems’ DANCE Trial at VIVA 2016

First Large-Scale Trial of the Bullfrog Micro-Infusion Device with Dexamethasone Shows Positive Results

EMERYVILLE, Calif., Sept. 21, 2016 /PRNewswire/ — Mercator MedSystems today announced that 13-month data from the DANCE trial was presented during a late-breaking scientific session at the Vascular Interventional Advances (VIVA) Annual Conference 2016 in Las Vegas, Nevada. DANCE is a prospective, multicenter, single-arm study designed to assess the clinical performance of the localized delivery of a generic steroid, dexamethasone, to the tissues around arteries that have been injured during endovascular interventions, using Mercator’s proprietary Bullfrog® Micro-Infusion Device.

Continue Reading

LIMBO-ATX Trial Begins in United States

Mercator MedSystems Announces First Patients Enrolled In U.S. Below The Knee (BTK) Clinical Trial In North Carolina And Texas

 EMERYVILLE, Calif., July 27, 2016 – Mercator MedSystems, Inc., has announced the enrollment of the first critical limb ischemia (CLI) patients in the LIMBO-ATX trial, the design of which was approved by the U.S. Food and Drug Administration (FDA) under an Investigation New Drug (IND) application. The study is designed to measure the benefit of localized drug delivery using the company’s proprietary Bullfrog® Micro-Infusion Device in combination with opening obstructed arteries in the lower leg. Patients were enrolled by Dr. George Adams at the University of North Carolina REX Hospital in Raleigh, NC and by Dr. Jason Yoho of the New Braunfels Cardiology Group at Guadalupe Regional Hospital in Seguin, TX, and both enrollments were in conjunction with an atherectomy procedure.

Continue Reading

Providence Medical Technology Announces Presentation of Two-Year Outcomes of Posterior Cervical Fusion for Single-Level Cervical Radiculopathy

Walnut Creek, CA (May 20, 2016) ‐‐ Providence Medical Technology, Inc., an innovator in tissue- sparing cervical fusion technology, today announced that its two-year radiographic and clinical outcomes data of posterior cervical fusion using an expandable implant are being presented at Spine Week 2016 in Singapore.

Continue Reading

Stryker Acquires SafeWire Product Portfolio for Use in Minimally-Invasive (MIS) Spine Procedures

Technology Used with Stryker’s Percutaneous ES2 Spinal Fixation System & LITe (Less Invasive Technologies) Procedural Solutions

ALLENDALE, N.J.–(BUSINESS WIRE)–Stryker’s Spine division today announced the acquisition of the SafeWire product portfolio, including the Y-Wire guidewire and Tiger Jamshidi Needle Family for use in minimally invasive spine surgery. The acquisition is highly complementary to Stryker’s current spine product portfolio and is aligned with the Spine division’s strategy of expanding its product offering for minimally-invasive spine surgery.

Continue Reading

LIMBO-PTA Trial Begins in Germany

Mercator MedSystems Announces First Patient Enrolled in Below the Knee (BTK) Clinical Trial

EMERYVILLE, Calif., Jan. 21, 2016 – Mercator MedSystems, Inc., has announced their first patient enrollment from Bad Krozingen, Germany, in the company’s LIMBO-PTA clinical trial. This trial combines localized drug delivery using the company’s proprietary Bullfrog® Micro-Infusion Device of an off-the-shelf anti-inflammatory steroid (dexamethasone) with angioplasty. The study measures the benefit of adding drug delivery to the catheter-based re-opening of arteries below the knee in patients suffering from critical limb ischemia (CLI).

Continue Reading

Providence Medical Technology Enhances Cervical Fusion Process With Introduction Of Proprietary Surface Technology to DTRAX Line of Tissue Sparing Devices

LAFAYETTE, Calif. — October 13, 2015 — Providence Medical Technology, Inc., an innovator in tissue-sparing cervical spine technology, today introduced its proprietary CavuxTM surface technology, designed to speed bone fusion during the healing process. The company’s portfolio of DTRAX® Cervical Cage implants will be available with Cavux, a unique surface technology that produces micro-textures on titanium surfaces. The micro- and nano- textures created across the implant surface area serve to enhance the fusion process.

Continue Reading

Providence Medical Technology Raises $12 Million Through a Combination of Equity and Debt Financing

Company Also Announces Appointment of Jason Hoffman as Vice President of Global Sales

LAFAYETTE, Calif. — August 26, 2015 — Providence Medical Technology, Inc., an innovator in tissue-sparing cervical spine technology, today announced the closing of $12 million in new financing for the company. The proceeds will be used to further commercialize and expand its portfolio of DTRAX® cervical fusion products designed to help patients suffering from cervical degenerative disc disease.

Continue Reading

Providence Medical Technology Launches DTRAX® Bone Screws to U.S. Market

New Bone Screws to Provide Supplemental Fixation for Joint Fusion

Lafayette, CA (May 29, 2015) ‐‐ Providence Medical Technology, Inc. today announced the full commercial launch of DTRAX Bone Screws in the U.S. market.

“This release represents an important step in broadening our platform of innovative, single-use instruments and implants for cervical fusion,” commented Jeff Smith, Chief Executive Officer of Providence Medical Technology. “Cervical fusion and indirect decompression with DTRAX products offers a compelling, tissue-sparing option for patients suffering from cervical radiculopathy.” Continue Reading

Scroll to top